THE RELATIONSHIP BETWEEN THE TIME OF USE OF ANTIRETROVIRAL THERAPY (ART) AND THE AMOUNT OF VIRAL LOAD IN ACQUIRED IMMUNODEFICIENCY SYNDROME

DIAN AYU JUWITA; YONANDA AINUL QALBI; NAJMIATUL FITRIA

doi:10.22159/ijap.2023.v15s1.47502

Authors

DIAN AYU JUWITA Department of Pharmacology and Clinical Pharmacy. Faculty of Pharmacy. Universitas Andalas. Indonesia
YONANDA AINUL QALBI Undergraduate Program, Faculty of Pharmacy. Universitas Andalas. Padang. Indonesia
NAJMIATUL FITRIA Department of Pharmacology and Clinical Pharmacy. Faculty of Pharmacy. Universitas Andalas. Indonesia

DOI:

https://doi.org/10.22159/ijap.2023.v15s1.47502

Keywords:

Antiretroviral therapy, Viral load, Duration of ARV, HIV

Abstract

Objective: Human Immunodeficiency Virus (HIV) that causes acquired immunodeficiency syndrome (AIDS) remains a health problem in the world, including in Indonesia, with increasing residents of people living with HIV/AIDS every year. Viral load measurement is a better predictor than clinical or immunological measures to evaluate the success or failure of ART. This study aimed to fig. out the sociodemographic characteristics and the relationship between the duration of antiretroviral therapy and viral load in HIV/AIDS patients.

Methods: A descriptive and analytic study with a retrospective approach was getting through in this research. There were 61 patients included in this study.

Results: As many as 86.89% of men reported having HIV infection. The biggest risk transmission factor through sexual intercourse by 100%. The most commonly used antiretroviral treatment is TDF+FTC+EFV (Tenofovir+Emtricitabine+Efavirenz) by 50,82%. There were 17 patients and 44 with detectable and undetectable results, respectively (p 0.05).

Conclusion: A statistical analysis of the duration of antiretroviral therapy and viral load concluded that the viral load decreases until it is undetectable with the longer use of ART.

Downloads

Download data is not yet available.

References

Siregar KN, Hanifah L, Rikawarastuti, Wahyuniar L. Prevention of HIV transmission from mother to child: challenges to the successful program implementation and practice in Indonesia. J Int Assoc Provid Aids Care. 2021;20:23259582211040701. doi: 10.1177/23259582211040701, PMID 34448424.

Barin F, Braibant M. HIV-1 antibodies in prevention of transmission. Curr Opin HIV AIDS. 2019 Jul;14(4):273-8. doi: 10.1097/COH.0000000000000553, PMID 30973417.

Jaimalai T, Meeroekyai S, Suree N, Prangkio P. Drug delivery system targeting CD4+ T cells for HIV-1 latency reactivation towards the viral eradication. J Pharm Sci. 2020 Oct;109(10):3013-20. doi: 10.1016/j.xphs.2020.06.019, PMID 32593715.

Doitsh G, Greene WC. Dissecting how CD4 T cells are lost during HIV infection. Cell Host Microbe. 2016;19(3):280-91. doi: 10.1016/j.chom.2016.02.012, PMID 26962940.

Jenderal D. Laporan perkembangan HIV AIDS and penyakit infeksi menular seksual (PIMS) triwulan I tahun. P2P. 2021.

WHO. HIV/AIDS. 2021.

Back D, Marzolini C. The challenge of HIV treatment in an era of polypharmacy. J Int AIDS Soc. 2020 Feb;23(2):e25449. doi: 10.1002/jia2.25449, PMID 32011104.

Atta MG, De Seigneux S, Lucas GM. Clinical pharmacology in HIV therapy. Clin J Am Soc Nephrol. 2019 Mar;14(3):435-44. doi: 10.2215/CJN.02240218, PMID 29844056.

Sempa JB, Rossouw TM, Lesaffre E, Nieuwoudt M. Cumulative viral load as a predictor of CD4+ T-cell response to antiretroviral therapy using Bayesian statistical models. Plos One. 2019;14(11):e0224723. doi: 10.1371/journal.pone. 0224723, PMID 31721805.

Eisinger RW, Dieffenbach CW, Anthony S, Fauci M. HIV viral load and transmissibility of HIV infection. Am Med Assoc. 2018;190(46):E1350-60.

Ford N, Orrell C, Shubber Z, Apollo T, Vojnov L. HIV viral re-suppression following an elevated viral load: a systematic review and meta-analysis. J Int AIDS Soc. 2019 Nov;22(11):e25415. doi: 10.1002/jia2.25415, PMID 31746541.

Friedman MR, Wei C, Klem ML, Silvestre AJ, Markovic N, Stall R. HIV infection and sexual risk among men who have sex with men and women (MSMW): A systematic review and meta-analysis. PLOS ONE. 2014;9(1):e87139. doi: 10.1371/journal.pone.0087139, PMID 24498030.

Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017 Dec;5(12):e1192-207. doi: 10.1016/S2214-109X(17)30375-3, PMID 29074409.

Liu C, Ma YL, Liu XH, Duan YR, Liu PL, Wang X. Sociodemographic factors associated with HIV/HCV high-risk behaviors among people who use drugs on methadone maintenance treatment: A 10 y observational study. Front Psychiatry. 2021;12:707257. doi: 10.3389/fpsyt.2021. 707257, PMID 34594250.

Gonçalves HM, Silva J, Pintado Maury I, Tavares A, Campos C, Sousa H. The prevalence and risk factors of oral HPV DNA detection among HIV-infected men between men who have sex with men and heterosexual men. Infect Dis (Lond). 2021 Jan;53(1):19-30. doi: 10.1080/23744235.2020.1811373, PMID 32915107.

Byrd KK, Hou JG, Hazen R, Kirkham H, Suzuki S, Clay PG. Antiretroviral adherence level necessary for HIV viral suppression using real-world data. J Acquir Immune Defic Syndr. 2019 Nov;82(3):245-51. doi: 10.1097/QAI.0000000000002142, PMID 31343455.

Kemenkes RI, Nomor PRI. Tahun 2014 tentang pedoman pengobatan antiretroviral. Vol. 87. Jakarta: Kementerian Kesehatan RI; 2014.

Julg B, Bogner JR. Atriplatrade mark–HIV therapy in one pill. Ther Clin Risk Manag. 2008;4(3):573-7. PMID 18827852.

Desriani, Azamris, Ghaissani SS, Kinanti SR, Warisman MA, Fitria N. Design and characterization of a SYBR Green I-based melting curve method for investigation of HER2I655V polymorphism in breast cancer. J Genet Eng Biotechnol. 2021 Jan;19(1):6. doi: 10.1186/s43141-020-00108-9, PMID 33428029.

Ali JH, Yirtaw TG. Time to viral load suppression and its associated factors in cohort of patients taking antiretroviral treatment in East Shewa zone, Oromiya, Ethiopia, 2018. BMC Infect Dis. 2019 Dec;19(1):1084. doi: 10.1186/s12879-019-4702-z, PMID 31881859.

Schultze A, Torti C, Cozzi Lepri A, Vandamme AM, Zazzi M, Sambatakou H. The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapy. AIDS. 2019 Feb;33(2):315-26. doi: 10.1097/QAD.0000000000002046, PMID 30325769.

Kittikraisak W, Kingkaew P, Teerawattananon Y, Yothasamut J, Natesuwan S, Manosuthi W. Health-related quality of life among patients with tuberculosis and hiv in Thailand. Plos One. 2012;7(1):e29775. doi: 10.1371/journal.pone.0029775, PMID 22253777.

Idrus L, Fitria N, Hasan N, Postma M, Alffenaar JW. PIN53 the usability testing of the integrated E-healthcare services (IEHS) web-based application in the therapy management of HIV and tuberculosis in Indonesia. Value Heal Reg Issues. 2020;22Suppl 57. doi: 10.1016/j.vhri.2020.07.300.

Nachega JB, Parienti JJ, Uthman OA, Gross R, Dowdy DW, Sax PE. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58(9):1297-307. doi: 10.1093/cid/ciu046, PMID 24457345.

Tan YM, Chong CP CY. Impact of hospital pharmacist-led home medication review program for people with schizophrenia. A prospective study from Malaysia. J Appl Pharm Sci. 2019;9(7):34-41.

WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV Infenction. Guidel. WHO. 2016.

Shoko C, Chikobvu D. Determinants of viral load rebound on HIV/AIDS patients receiving antiretroviral therapy: results from South Africa. Theor Biol Med Model. 2018 Jul;15(1):10. doi: 10.1186/s12976-018-0082-0, PMID 30008270.

Hayden RT, Yan X, Wick MT, Rodriguez AB, Xiong X, Ginocchio CC. Factors contributing to variability of quantitative viral PCR results in proficiency testing samples: a multivariate analysis. J Clin Microbiol. 2012;50(2):337-45. doi: 10.1128/JCM.01287-11, PMID 22116152.